Teva Pharmaceutical Industries (TEVA) Long-Term Investments (2009 - 2012)

Teva Pharmaceutical Industries (TEVA) has reported Long-Term Investments for 4 consecutive years, with $1.2 billion the latest figure, recorded in Q3 2012.

• For the quarter ending Q3 2012, Long-Term Investments rose 105.09% year-over-year to $1.2 billion; the trailing twelve-month figure through Sep 2012 stood at $1.2 billion (up 105.09% YoY), and the FY2011 full-year result was $991.0 million, up 56.8% from the prior year.
• Long-Term Investments advanced to $1.2 billion in Q3 2012 per TEVA's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Long-Term Investments topped out at $1.2 billion in Q3 2012 and bottomed at $406.0 million in Q1 2009.
• Historically, Long-Term Investments has averaged $717.1 million across 4 years, with a median of $650.0 million in 2011.
• The sharpest annual moves came in 2011 and 2012: Long-Term Investments decreased 13.38% in 2011, then surged 105.09% in 2012.
• Over 4 years, Long-Term Investments stood at $534.0 million in 2009, then gained by 18.35% to $632.0 million in 2010, then surged by 56.8% to $991.0 million in 2011, then advanced by 21.9% to $1.2 billion in 2012.
• According to Business Quant data, Long-Term Investments over the past three periods registered $1.2 billion, $1.1 billion, and $1.0 billion for Q3 2012, Q2 2012, and Q1 2012 respectively.